46 related articles for article (PubMed ID: 38493554)
1. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
[TBL] [Abstract][Full Text] [Related]
2. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
[TBL] [Abstract][Full Text] [Related]
3. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
[TBL] [Abstract][Full Text] [Related]
4. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
Evdoshenko EP; Neofidov NA; Bakhtiyarova KZ; Davydovskaya MV; Kairbekova EI; Kolontareva YM; Malkova NA; Odinak MM; Popova EV; Sazonov DV; Stolyarov ID; Smagina IV; Fedyanin AS; Habirov FA; Khaibullin TI; Khachanova NV; Shchukin IA; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
[TBL] [Abstract][Full Text] [Related]
5. [The first russian experience of use of siponimod in real clinical practice].
Prakhova LN; Ilves AG
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):138-141. PubMed ID: 35904305
[TBL] [Abstract][Full Text] [Related]
6. Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
Chang EH; Hardy TA
J Neuroimmunol; 2024 Apr; 389():578330. PubMed ID: 38493554
[TBL] [Abstract][Full Text] [Related]
7. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Krasnov VS; Kolontareva YM
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
[TBL] [Abstract][Full Text] [Related]
8. Siponimod for multiple sclerosis.
Cao L; Li M; Yao L; Yan P; Wang X; Yang Z; Lao Y; Li H; Yang K; Li K
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013647. PubMed ID: 34783010
[TBL] [Abstract][Full Text] [Related]
9. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
Scott LJ
CNS Drugs; 2020 Nov; 34(11):1191-1200. PubMed ID: 33108633
[TBL] [Abstract][Full Text] [Related]
10. Siponimod in the treatment of multiple sclerosis.
Goodman AD; Anadani N; Gerwitz L
Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
[No Abstract] [Full Text] [Related]
11. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
